Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR446959 · 1 trial · 1 indication
Assessment of adverse events (AE) / treatment-emergent adverse events (TEAE).
Count of PCSAs and descriptive statistics will be done on clinical laboratory, vital signs and 12-Lead ECG parameters.
| Arm | Type | Description |
|---|---|---|
| SAR446959 | EXPERIMENTAL | Participants will receive a single intra-articular dose of SAR446959 on Day 1 |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a single intra-articular dose of placebo on Day 1. The injection volume of the placebo will be the same as the injection volume for SAR446959 in the corresponding dose level cohort. |
| Name | Type | Description |
|---|---|---|
| SAR446959 | DRUG | Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection |
| Placebo | DRUG | Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection |
Inclusion Criteria: Participants must have a diagnosis of primary knee osteoarthritis, based on the American College of Rheumatology Clinical criteria using history and physical examination in the index knee * Participants must have index knee OA symptoms since at least 6 months before screening. *...
SAR446959 is an investigational small molecule being developed for the treatment of osteoarthritis. It is being studied in participants with osteoarthritis of the knee. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
SAR446959 is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and tolerability of this investigational drug for osteoarthritis.
SAR446959 is in Phase 1 clinical development. A first-in-human study has been completed to investigate its safety and tolerability in participants with osteoarthritis of the knee. The drug is investigational and has not been approved for any use.
SAR446959 has one completed clinical trial registered under NCT06704932. This was a Phase 1, first-in-human study that evaluated the safety and tolerability of the drug in 32 participants with osteoarthritis of the knee. The trial was conducted in Germany.
No alternative names for SAR446959 have been disclosed. The drug is identified by its development code SAR446959 and is being studied under the clinical trial identifier NCT06704932. It is a distinct investigational compound being developed by Sanofi.